Peer-reviewed
Publications
Company-linked, peer-reviewed research. Summaries are original paraphrases; follow the links for the full records.
All four studies are preclinical. They do not establish clinical efficacy or regulatory authorisation, and TXB2/TXB4 results are not human TXP1 trials.
2021
FASEB J
- Online:
- 25 November 2020
- Issue:
- 2021 Feb
- Shuttle variant:
- TXB2
- Model:
- mouse
Blood-brain barrier transport using a high affinity, brain-selective VNAR antibody targeting transferrin receptor 1.
Stocki P, Szary J, Rasmussen CLM, Demydchuk M, Northall L, Logan DB, Gauhar A, Thei L, Moos T, Walsh FS, Rutkowski JL.
TXB2 selection and delivery experiments in mice support TfR1-mediated brain transport. Peripheral biodistribution in this earlier scaffold included a lung exception.
2020
FASEB J
- Online:
- 11 August 2020
- Issue:
- 2020 Oct
- Shuttle variant:
- TXB2
- Model:
- mouse
Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle.
Sehlin D, Stocki P, Gustavsson T, Hultqvist G, Walsh FS, Rutkowski JL, Syvänen S.
Mouse experiments compared TXB2 fusion formats and antibody cargo delivery. Results depend on cargo and timepoint.
2022
Pharmaceutics
- Online:
- 24 June 2022
- Issue:
- 2022 Jun
- Shuttle variant:
- TXB4-TrkB
- Model:
- 6-OHDA mouse
A Single Domain Shark Antibody Targeting the Transferrin Receptor 1 Delivers a TrkB Agonist Antibody to the Brain and Provides Full Neuroprotection in a Mouse Model of Parkinson's Disease.
Clarke E, Stocki P, Sinclair EH, Gauhar A, Fletcher EJR, Krawczun-Rygmaczewska A, Duty S, Walsh FS, Doherty P, Rutkowski JL.
A TXB4-TrkB fusion was tested in a 6-OHDA mouse model with neuronal-survival readouts. It concerns TXB4 in mice, not a clinical TXP1 Parkinson’s treatment.
2023
Pharmaceutics
- Online:
- 23 February 2023
- Issue:
- 2023 Feb
- Shuttle variant:
- TXB2 / TXB4
- Model:
- mouse
CDR3 Variants of the TXB2 Shuttle with Increased TfR1 Association Rate and Enhanced Brain Penetration.
Stocki P, Szary J, Demydchuk M, Northall L, Rasmussen CLM, Logan DB, Gauhar A, Thei L, Coker SF, Moos T, Walsh FS, Rutkowski JL.
CDR3 engineering of TXB2 yielded variants including TXB4 with increased brain exposure in mice; effects varied across fused antibodies.